In good news for those averse to injections, GLP-1 agonist medication is a step closer to being offered in oral pill form, ...

While 1 in 10 Americans have diabetes, the rate in South Texas is much higher—estimated at 1 in 3 to 1 in 4 adults.

AstraZeneca and Viking Therapeutics both presented encouraging data on their obesity pills. Meanwhile, here’s how Americans ...

Obesity caused by a lifestyle of moving less and eating more is a prime factor contributing to Type 2 diabetes. Is the answer ...

The pharmaceutical company Viking has recently become one of the most volatile stocks on Wall Street due to the announcement ...

Novo Nordisk said the side effects in trials so far for its experimental obesity drug CagriSema were similar to its GLP-1 ...

In a new study, researchers at the University of Copenhagen have been cultivating 'good viruses' from feces. The goal is to ...

The U.K.-based company released the data at Obesity Week, an event organized by the Obesity ... after investors were underwhelmed by early data from a trial of a weight-loss pill.

AstraZeneca’s new obesity pill, licensed from China’s Eccogene last year, has shown initial promise in early-stage trials.